---
title: "GHRP-6"
canonical_url: https://peptidelibrary.app/library/ghrp-6
description: "Synthetic hexapeptide growth hormone secretagogue and one of the earliest compounds in its class. It raises growth hormone through the ghrelin receptor, and because that is the receptor ghrelin uses to signal hunger it also produces marked appetite stimulation and increased gastric motility, along with rises in cortisol and prolactin. Those off-target effects prompted development of more selective agents such as ipamorelin. Not FDA-approved. Prohibited in sport under WADA class S2."
updated: 2026-09-06
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# GHRP-6

GHRP-6 (also called Growth hormone-releasing peptide-6 or SK&F 110679) is a ghrelin-receptor agonist in the Growth Hormone Secretagogue class. GHRP-6 is a synthetic hexapeptide agonist at growth hormone secretagogue receptor 1a. It stimulates growth hormone release both directly at the pituitary and indirectly by suppressing somatostatin tone in the hypothalamus.

Synthetic hexapeptide growth hormone secretagogue and one of the earliest compounds in its class. It raises growth hormone through the ghrelin receptor, and because that is the receptor ghrelin uses to signal hunger it also produces marked appetite stimulation and increased gastric motility, along with rises in cortisol and prolactin. Those off-target effects prompted development of more selective agents such as ipamorelin. Not FDA-approved. Prohibited in sport under WADA class S2.

Also known as: Growth hormone-releasing peptide-6, SK&F 110679.

Categories: Fat Loss, Muscle/Recovery, Experimental.

## Classification

- Type: Ghrelin-receptor agonist / research
- Mechanism class: Growth Hormone Secretagogue
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

GHRP-6 is a synthetic hexapeptide agonist at growth hormone secretagogue receptor 1a. It stimulates growth hormone release both directly at the pituitary and indirectly by suppressing somatostatin tone in the hypothalamus. Its selectivity is limited relative to later compounds in the class: alongside growth hormone it commonly raises cortisol and prolactin, and it produces pronounced appetite stimulation and increased gastric motility, consistent with activating the receptor that ghrelin normally uses to signal hunger. Those off-target effects are the reason more selective agonists such as ipamorelin were subsequently developed.

Targets: GHSR (ghrelin receptor).

Origin: Synthetic Met-enkephalin-derived hexapeptide.

## Properties

- Molecular formula: C46H56N12O6
- Molecular weight: 873.0 g/mol
- CAS number: 87616-84-0
- Half-life: ~30 minutes
- Studied routes: Intravenous

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Early or uncontrolled human studies
- Human trials: 3
- Controlled human trials: 0
- Preclinical sources: 0
- Latest source: 2013

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Cabrales A et al. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 2013. 2013. Human study (early or uncontrolled). Population: Nine male healthy volunteers. Pharmacokinetic profile of GHRP-6 [Source](https://pubmed.ncbi.nlm.nih.gov/23099431/)
2. Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release. Pituitary. 2010. 2010. Human study (early or uncontrolled). Population: Human subjects. Growth hormone, ACTH and cortisol responses versus ghrelin and GHRH [Source](https://pubmed.ncbi.nlm.nih.gov/20602173/)
3. Diagnosis of adrenal insufficiency using the GHRP-6 test: comparison with the insulin tolerance test. Horm Metab Res. 2010. 2010. Human study (early or uncontrolled). Population: Patients assessed for adrenal insufficiency. Diagnostic performance versus the insulin tolerance test [Source](https://pubmed.ncbi.nlm.nih.gov/19946832/)

## Safety

Side effects: Marked hunger; Water retention; Cortisol increase.

Risks: WADA S2 prohibited.

Contraindications: May increase appetite; Avoid with diabetes.

Human safety basis: Limited human reports

Key limitations: No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

GHRP-6 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is GHRP-6?

Synthetic hexapeptide growth hormone secretagogue and one of the earliest compounds in its class. It raises growth hormone through the ghrelin receptor, and because that is the receptor ghrelin uses to signal hunger it also produces marked appetite stimulation and increased gastric motility, along with rises in cortisol and prolactin. Those off-target effects prompted development of more selective agents such as ipamorelin. Not FDA-approved. Prohibited in sport under WADA class S2.

### How does GHRP-6 work?

GHRP-6 is a synthetic hexapeptide agonist at growth hormone secretagogue receptor 1a. It stimulates growth hormone release both directly at the pituitary and indirectly by suppressing somatostatin tone in the hypothalamus.

### Is GHRP-6 FDA approved?

No. GHRP-6 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. FDA's compounding lists show 503A Category 3: Nominated without adequate support; 503B Category 2: FDA identified significant safety risks.

### What is the half-life of GHRP-6?

Reported half-life for GHRP-6 is ~30 minutes. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is GHRP-6 banned in sport?

GHRP-6 is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to GHRP-6?

Compounds most often compared with GHRP-6 include Ipamorelin, GHRP-1, Pralmorelin (GHRP-2) and Hexarelin (Examorelin). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism — Clin Endocrinol (Oxf), 1997](https://pubmed.ncbi.nlm.nih.gov/9156038/)
- [Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation — J Nanobiotechnology, 2025](https://pubmed.ncbi.nlm.nih.gov/41327290/)
- [Disposition of growth hormone-releasing peptide (SK&F 110679) in rat and dog following intravenous or subcutaneous administration — Drug Metab Dispos, 1994](https://pubmed.ncbi.nlm.nih.gov/8149896/)
- [Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms — Front Pharmacol, 2024](https://pubmed.ncbi.nlm.nih.gov/38873418/)
- [Inhibition of ghrelin activity by the receptor antagonist \[D-Lys3\]-GHRP-6 enhances hepatic fatty acid oxidation and gluconeogenesis in a growing pig model — Peptides, 2023](https://pubmed.ncbi.nlm.nih.gov/37301480/)
